ライフサイエンスコーパス: posaconazole

1 whereas all three were inhibited by 1 mug/ml posaconazole.

2 e analysis: 19 received ABLC and 21 received posaconazole.

3 ofungin, 98.2% for micafungin, and 98.1% for posaconazole.

4 ates of Candida albicans were tested against posaconazole.

5 en the Vitek 2 and BMD methods was 95.6% for posaconazole.

6 micafungin and after 48 h of incubation for posaconazole.

7 = 1 microg/ml was used for amphotericin and posaconazole.

8 s, including voriconazole, itraconazole, and posaconazole.

9 of < or = 0.25 microg/ml was established for posaconazole.

10 in three patients and in one, termination of posaconazole.

11 redict the susceptibility of Candida spp. to posaconazole.

12 71 clinical isolates of Candida spp. against posaconazole.

13 g the susceptibility of filamentous fungi to posaconazole.

14 r susceptibility testing of the new triazole posaconazole.

15 traconazole, voriconazole, ravuconazole, and posaconazole.

16 r reduced susceptibility to itraconazole and posaconazole.

17 han three dilutions) was also low (<2%) with posaconazole.

18 nd progression of IA after switching to oral posaconazole.

19 ophylaxis, 9.3% on voriconazole, and 8.5% on posaconazole.

20 ing in resistant strains, in comparison with posaconazole.

21 ngal treatment that included voriconazole or posaconazole.

22 er benznidazole monotherapy or combined with posaconazole.

23 photoactivatable cross-linking derivative of posaconazole.

24 midine, and two antifungals ravuconazole and posaconazole.

25 ilar to that reported for amphotericin B and posaconazole.

26 e who were changed to either itraconazole or posaconazole.

27 pectively), itraconazole (0.5 and 1 mug/ml), posaconazole (0.5 and 1 mug/ml), isavuconazole (4 and 4

28 er than the ECVs ranged from 1.1 to 5.7% for posaconazole, 0.0 to 1.6% for voriconazole, and 0.7 to 4

29 rog/ml; itraconazole, 0.06 to 0.5 microg/ml; posaconazole, 0.03 to 0.25 microg/ml; voriconazole, 0.01

30 /4 (94.8%); voriconazole, 0.03/0.12 (98.6%); posaconazole, 0.12/0.5 (95.9%); amphotericin, 0.5/2 (88.

31 (97.7%); A. flavus, itraconazole, 1 (99.6%); posaconazole, 0.25 (95%); voriconazole, 1 (98.1%); A. ni

32 2 (99.3%); A. niger, itraconazole, 2 (100%); posaconazole, 0.5 (96.9%); voriconazole, 2 (99.4%); A. t

33 ses): A. fumigatus, itraconazole, 1 (98.8%); posaconazole, 0.5 (99.2%); voriconazole, 1 (97.7%); A. f

34 (99.4%); A. terreus, itraconazole, 1 (100%); posaconazole, 0.5 (99.7%); voriconazole, 1 (99.1%); A. v

35 (98.1%); A. nidulans, itraconazole, 1 (95%); posaconazole, 1 (97.7%); voriconazole, 2 (99.3%); A. nig

36 .1%); A. versicolor, itraconazole, 2 (100%); posaconazole, 1 (not applicable); voriconazole, 2 (97.5%

37 te experiment, guinea pigs were treated with posaconazole (10 mg/kg of body weight orally [p.o.] twic

38 and 89.3%); all were superior to placebo or posaconazole (10% and 16.7%, p < 0.0001).

39 otherapy (both 96%) versus placebo (17%) and posaconazole (16%, p < 0.0001).

40 en/probable mold infections were considered (posaconazole, 2.7% vs itraconazole, 10.7%, P= .02).

41 B (18 to 25 mm), itraconazole (11 to 21 mm), posaconazole (28 to 35 mm), and voriconazole (25 to 33 m

42 B (18 to 27 mm), itraconazole (18 to 26 mm), posaconazole (28 to 38 mm), and voriconazole (29 to 39 m

43 5 to 24 mm), itraconazole (20 to 31 mm), and posaconazole (33 to 43 mm); A. fumigatus ATCC MYA-3626,

44 placebo b.i.d.; benznidazole 200 mg b.i.d. + posaconazole 400 mg b.i.d.; or placebo 10 mg b.i.d. T. c

45 a and Spain who were randomized to 4 groups: posaconazole 400 mg twice a day (b.i.d.); benznidazole 2

46 er), and 48 h (other species); and (iii) the posaconazole 5-microg disk, voriconazole 1-microg disk,

47 pofungin 5-microg disks [BBL and Oxoid], and posaconazole 5-microg disks).

48 aracteristics of voriconazole (10 mg/mL) and posaconazole (6, 12 mg/mL) solutions.

49 requently had hypertension prior to starting posaconazole (68.8% vs 32.1%, P = .009).

50 requently had hypertension prior to starting posaconazole (68.8% vs 32.1%, P=0.009).

51 The object of this study was to test whether posaconazole, a broad-spectrum antifungal agent inhibiti

52 ant to the ergosterol biosynthesis inhibitor posaconazole, a drug proposed for use against T. cruzi i

53 r study, we evaluated efficacy and safety of posaconazole, a new extended-spectrum triazole, as salva

54 Posaconazole absorption was assessed on day 14.

55 Posaconazole accumulates at high concentrations in dHL-6

56 to validate a potential surrogate marker for posaconazole activity against indicated species.

57 the 90% effective concentration threshold of posaconazole activity against R. oryzae could be achieve

58 adjacent bone was treated successfully with posaconazole after therapy with itraconazole and amphote

59 roth microdilution susceptibility testing of posaconazole against 146 clinical isolates of filamentou

60 le against 55 (60%) of the 91 isolates, with posaconazole against 46 (51%) of the 91 isolates, and wi

61 bited a remarkable synergistic activity with posaconazole against all tested C. auris isolates and ot

62 tion, E-test, and disk diffusion methods for posaconazole against Candida spp.

63 al and clinical studies indicate activity of posaconazole against Fusarium.

64 thway, would enhance the in vivo activity of posaconazole against Rhizopus oryzae, the Mucorales spec

65 For MIC-0 of posaconazole, agreement levels were 86% for the 6-h XTT

66 g the susceptibility of filamentous fungi to posaconazole; agreement (+/-2 log2 dilutions) between th

67 rpose of this study was to determine whether posaconazole alone or combined with benznidazole were su

68 in the fly model of mucormycosis (65% vs 57% posaconazole alone) and with significant reductions in c

69 e for emergence of reduced susceptibility to posaconazole among Candida spp.

70 to fluconazole, voriconazole, itraconazole, posaconazole, amphotericin B, and caspofungin for 383 in

71 tly enhanced the activity of the antifungals posaconazole, amphotericin B, and caspofungin, likely th

72 tro activities of fluconazole, voriconazole, posaconazole, amphotericin B, anidulafungin, caspofungin

73 reover, they both acted synergistically with posaconazole, an azole currently used in the treatment o

74 Only 13.3% of those receiving posaconazole and 10% receiving placebo achieved the prim

75 percentage of breakthrough IFDs (18.9% with posaconazole and 38.7% with itraconazole, P< .001).

76 ysis, 90% of the patients receiving low-dose posaconazole and 80% of those receiving high-dose posaco

77 ysis, 92% of the patients receiving low-dose posaconazole and 81% receiving high-dose posaconazole, a

78 , compared with 80% receiving benznidazole + posaconazole and 86.7% receiving benznidazole monotherap

79 ution and agar diffusion methods for testing posaconazole and amphotericin B in the clinical laborato

80 substantially less expensive to produce than posaconazole and are appropriate for further development

81 After failing posaconazole and being intolerant to amphotericin, he wa

82 was not observed at 360 days; benznidazole + posaconazole and benznidazole monotherapy (both 96%) ver

83 cutaneous H. aspergillata infection while on posaconazole and caspofungin therapy.

84 verall agreement was lower between reference posaconazole and Etest MICs (94 to 97%) and by both meth

85 rrence of PIPH in outpatients newly starting posaconazole and evaluated differences in serum posacona

86 eronism (PIPH) in outpatients newly starting posaconazole and evaluated differences in serum posacona

87 fficacy of antifungal prophylaxis (AFP) with posaconazole and itraconazole in a real-life setting of

88 By comparison, posaconazole and itraconazole resolved GM antigenemia, r

89 conazole and voriconazole and 90 to 91% with posaconazole and itraconazole when EUCAST MICs were comp

90 When comparing the groups taking posaconazole and itraconazole, there were no significant

91 fective against Chagas, and antifungal drugs posaconazole and ravuconazole have entered clinical tria

92 Combinations of posaconazole and tacrolimus were synergistic in checkerb

93 growth inhibition and fungicidal activity of posaconazole and tacrolimus, alone and in combination, a

94 The specific subcellular location of posaconazole and the mechanism by which cell-associated

95 The MIC results obtained for both posaconazole and voriconazole after only 24 h of incubat

96 performed 24- and 48-h MIC determinations of posaconazole and voriconazole against more than 16,000 c

97 ng 13 species rarely isolated from blood, to posaconazole and voriconazole as well as four licensed s

98 which itraconazole MICs were >2 mug/ml, the posaconazole and voriconazole MICs were greater than the

99 onazole MICs were < or = 2 microg/ml against posaconazole and voriconazole using the CLSI BMD method.

100 Posaconazole and voriconazole were active (MIC, < or = 1

101 had MICs equal to or less than the ECV]) for posaconazole and voriconazole, respectively, were as fol

102 The modal MICs (mug/ml) for posaconazole and voriconazole, respectively, were as fol

103 We tested 16,191 strains of Candida against posaconazole and voriconazole, using the CLSI M27-A3 bro

104 the 24- and 48-h results was 99.6% for both posaconazole and voriconazole.

105 ecies-specific clinical breakpoints for both posaconazole and voriconazole.

106 Aspergillus spp. were comparable to those of posaconazole and voriconazole; the MIC90 values for isav

107 uconazole was the weakest inhibitor, whereas posaconazole and VT-1161 were the strongest CYP51 inhibi

108 ructures of C. albicans CYP51 complexes with posaconazole and VT-1161, providing a molecular mechanis

109 in a three-dilution range) between reference posaconazole and YeastOne MICs was 98 to 100% at 16 to 2

110 oriconazole, ketoconazole, itraconazole, and posaconazole) and topically (miconazole and clotrimazole

111 2 dilutions and 99.6% (itraconazole), 87.7% (posaconazole), and 96.3% (voriconazole) at +/-1 dilution

112 s was excellent: 100% (itraconazole), 98.4% (posaconazole), and 99.6% (voriconazole) assessing EA at

113 Voriconazole, posaconazole, and ravuconazole all were very active (99%

114 n B, flucytosine, fluconazole, voriconazole, posaconazole, and ravuconazole were determined by the Na

115 conazole, three new triazoles (voriconazole, posaconazole, and ravuconazole), and amphotericin B.

116 dida spp. against fluconazole, voriconazole, posaconazole, and ravuconazole.

117 ndida spp to the new triazoles voriconazole, posaconazole, and ravuconazole.

118 onazole; the MIC90 values for isavuconazole, posaconazole, and voriconazole against Candida spp. were

119 eptibility testing methods for itraconazole, posaconazole, and voriconazole by testing 245 Aspergillu

120 o compare MICs of fluconazole, itraconazole, posaconazole, and voriconazole obtained by the European

121 with CLSI BMD method M27-A3 for fluconazole, posaconazole, and voriconazole susceptibility testing of

122 Testing of susceptibility to amphotericin B, posaconazole, and voriconazole was subsequently performe

123 developed ECVs for triazoles (itraconazole, posaconazole, and voriconazole) and common Aspergillus s

124 ngin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazole) using CLSI methods.

125 the EUCAST and CLSI results for fluconazole, posaconazole, and voriconazole, respectively, for each s

126 ECVs (expressed as mug/ml) for fluconazole, posaconazole, and voriconazole, respectively, were as fo

127 entages of non-WT isolates for itraconazole, posaconazole, and voriconazole, respectively, were as fo

128 for five Aspergillus spp. and itraconazole, posaconazole, and voriconazole.

129 o amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole.

130 ketoconazole, itraconazole, voriconazole, or posaconazole; and dronedarone.

131 apsilosis) were susceptible to voriconazole, posaconazole, anidulafungin, caspofungin, and micafungin

132 14alpha-demethylase (CYP51), complexed with posaconazole, another antifungal agent fluconazole and a

133 ompounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Ch

134 Here we show that posaconazole, another triazole, also blocks cholesterol

135 n the basis of compassionate treatment data, posaconazole appears to be effective for treatment of zy

136 le and intravenous or delayed release tablet posaconazole are recommended with moderate strength.

137 One patient in the ABLC arm and none in posaconazole arm developed IFI (5% vs. 0%, P=0.48).

138 cal Evaluation Trial, and bring attention to posaconazole as a potential complementary anti-breast ca

139 l trial to assess the efficacy and safety of posaconazole as compared with the efficacy and safety of

140 ose posaconazole and 81% receiving high-dose posaconazole, as compared with 38% receiving benznidazol

141 onazole and 80% of those receiving high-dose posaconazole, as compared with 6% receiving benznidazole

142 present work we cocrystallized the P450 with posaconazole at 2.5 A resolution.

143 400 mg twice daily (high-dose posaconazole), posaconazole at a dose of 100 mg twice daily (low-dose p

144 We randomly assigned patients to receive posaconazole at a dose of 400 mg twice daily (high-dose

145 We compared the crystal structure of posaconazole-bound CYP46A1 with those of the P450 in com

146 ours and could be competitively inhibited by posaconazole but not voriconazole.

147 ions (MECs) of amphotericin B, voriconazole, posaconazole, caspofungin, and micafungin were assessed

148 (amphotericin B, fluconazole, voriconazole, posaconazole, caspofungin, anidulafungin, and micafungin

149 Posaconazole monotherapy or posaconazole combined with benznidazole achieved high RT

150 Posaconazole concentrates within host cell membranes and

151 The antifungal posaconazole concentrates within host cells and protects

152 aconazole and evaluated differences in serum posaconazole concentrations and clinical characteristics

153 aconazole and evaluated differences in serum posaconazole concentrations and clinical characteristics

154 development is associated with higher serum posaconazole concentrations, older age, and baseline hyp

155 HL-60] cells) and then exposed to a range of posaconazole concentrations.

156 oaded ex vivo with the lipophilic antifungal posaconazole could improve delivery of antifungals to th

157 Our results suggest posaconazole could replace fluconazole in the treatment

158 In addition, posaconazole cured 33% of N. fowleri-infected mice at a

159 ketoconazole, itraconazole, voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromyc

160 Amphotericin B and posaconazole demonstrated species-specific and inter-spe

161 Posaconazole demonstrated trypanostatic activity during

162 order to propose quality control limits for posaconazole disk diffusion susceptibility tests on Muel

163 three lots of prepared media using 5-microg posaconazole disks in each of eight laboratories to gene

164 r, its occurrence and association with serum posaconazole drug levels has not previously been investi

165 r, its occurrence and association with serum posaconazole drug levels have not previously been invest

166 For A. fumigatus, posaconazole E-test MICs had better concordance with ref

167 rast, with amphotericin B, itraconazole, and posaconazole, E-test results were more dependent on the

168 B (EA, 100%), voriconazole (EA, 93.7%), and posaconazole (EA, 94.8%) against C. albicans, but its er

169 A posaconazole ECV of 0.5 mg/L was used as no CLSI ECV was

170 Posaconazole EUCAST MICs were also substantially lower t

171 Our studies reported here demonstrate that posaconazole exhibits in vitro synergy with caspofungin

172 teractions determine the submicromolar Kd of posaconazole for CYP46A1.

173 RD9 deficiency and the potential efficacy of posaconazole for this indication.

174 Contact-dependent transfer of posaconazole from dHL-60 cells to hyphae was observed in

175 ay 14, except for 2 patients in the low-dose posaconazole group who tested positive on day 60.

176 arison of the benznidazole group with either posaconazole group).

177 arison of the benznidazole group with either posaconazole group); in the per-protocol analysis, 90% o

178 However, significantly more patients in the posaconazole groups than in the benznidazole group had t

179 ecause of severe cutaneous reactions; in the posaconazole groups, 4 patients had aminotransferase lev

180 e same isolates had MICs to voriconazole and posaconazole > or = 2 microg/ml.

181 Posaconazole has been approved for prophylaxis in HSCT.

182 Posaconazole has shown trypanocidal activity in murine m

183 of combination therapy with benznidazole and posaconazole have not been tested in Trypanosoma cruzi c

184 otericin; newer triazoles (ie, voriconazole, posaconazole) have been demonstrated to be useful in ref

185 The new triazole agents, voriconazole and posaconazole, have a broad spectrum of antifungal activi

186 riconazole are in the same triazole class as posaconazole, have CLSI-approved interpretive MIC breakp

187 The availability of posaconazole in an oral formulation that can be administ

188 We also analyzed the accommodation of posaconazole in the active site of the target enzymes, C

189 fluconazole, itraconazole, voriconazole, and posaconazole in vitro.

190 ational study, we examined the occurrence of posaconazole-induced pseudohyperaldosteronism (PIPH) in

191 There have been case reports of posaconazole-induced pseudohyperaldosteronism (PIPH); ho

192 There have been case reports of posaconazole-induced pseudohyperaldosteronism, however,

193 e and the mechanism by which cell-associated posaconazole inhibits fungal growth remain uncharacteriz

194 Posaconazole is associated with secondary hypertension a

195 Posaconazole is widely used for prophylaxis against inva

196 ution method for itraconazole, voriconazole, posaconazole, isavuconazole, ketoconazole, terbinafine,

197 Voriconazole, posaconazole, itraconazole, amphotericin B, and micafung

198 A. nidulans, and A. terreus to voriconazole, posaconazole, itraconazole, and amphotericin B by the E-

199 The antifungal azoles, posaconazole, itraconazole, and ketoconazole, significan

200 Treatment with posaconazole led to complete resolution of the lesions.

201 PIPH had a significantly higher median serum posaconazole level than those without PIPH (3.0 vs 1.2 u

202 PIPH had a significantly higher median serum posaconazole level than those without PIPH (3.0 vs 1.2 u

203 = .01), a negative correlation between serum posaconazole levels and changes in serum potassium (r =

204 =0.01), a negative correlation between serum posaconazole levels and changes in serum potassium (r =-

205 ere was a positive correlation between serum posaconazole levels and changes in systolic blood pressu

206 ere was a positive correlation between serum posaconazole levels and changes in systolic blood pressu

207 6), and a positive correlation between serum posaconazole levels and serum 11-deoxycortisol (r = .69,

208 6), and a positive correlation between serum posaconazole levels and serum 11-deoxycortisol (r =.69,

209 Posaconazole levels in dHL-60 cells were 265-fold greate

210 Posaconazole-loaded cells were viable and maintained the

211 utropenic mouse model of IPA, treatment with posaconazole-loaded dHL-60 cells resulted in significant

212 These findings suggest that posaconazole-loading of leukocytes may hold promise for

213 We compared posaconazole M27-A2 and M38-A MICs to Etest and YeastOne

214 Posaconazole may also be used in those age 13 years or o

215 Fluconazole, voriconazole, and posaconazole MIC results for 10,807 isolates of Candida

216 n and micafungin MICs among Candida spp. and posaconazole MICs among C. albicans isolates and demonst

217 on coefficient was similar between reference posaconazole MICs and either disk (R, 0.810) or tablet (

218 Voriconazole and posaconazole MICs were 0.5-4 and 0.06-0.5 mg/L, respecti

219 olates of Candida spp. with a broad range of posaconazole MICs were tested using the CLSI M27-A2 meth

220 Posaconazole monotherapy or posaconazole combined with b

221 burden, compared with animals that received posaconazole monotherapy, in the cutaneous model of muco

222 c malignancies taking voriconazole (n = 20), posaconazole (n = 8), and itraconazole (n = 4), and a he

223 one or more doses of study drug (n=288 [50%] posaconazole, n=287 [50%] voriconazole).

224 rmediate of an orally active antifungal drug posaconazole (Noxafil).

225 ive mold infections (IMIs) that occur during posaconazole or voriconazole prophylaxis are rare compli

226 ent with apical PC945 and either basolateral posaconazole or voriconazole resulted in a synergistic i

227 raction observed when apical and basolateral posaconazole or voriconazole were combined.

228 d prophylactic treatment with PC945, but not posaconazole or voriconazole, showed superior effects to

229 le at a dose of 100 mg twice daily (low-dose posaconazole), or benznidazole at a dose of 150 mg twice

230 ns (MGCD290 in combination with fluconazole, posaconazole, or voriconazole) was performed by the chec

231 t of, standard antifungal therapies received posaconazole oral suspension (40 mg/mL) 800 mg daily in

232 g/kg of intravenous ABLC weekly or 200 mg of posaconazole orally three times per day as prophylaxis f

233 le (FL), itraconazole (I), voriconazole (V), posaconazole (P), flucytosine (FC), caspofungin (C), and

234 ing benznidazole monotherapy (p < 0.0001 vs. posaconazole/placebo).

235 Posaconazole plus MGCD290 demonstrated synergy against 1

236 eceiving ISA was compared to those receiving posaconazole (POS) and voriconazole (VOR) during the sam

237 oxaborale AN4169 cured 100% of mice, whereas posaconazole (POS), and NTLA-1 (a nitro-triazole) cured

238 MB), itraconazole (ITR), voriconazole (VOR), posaconazole (POS), and ravuconazole (RAV).

239 oles, fluconazole (FLC), itraconazole (ITC), posaconazole (POS), and voriconazole (VOR), was examined

240 oth dilution method with itraconazole (ITR), posaconazole (POS), ravuconazole (RAV), and voriconazole

241 (A Study of the Use of Oral Posaconazole [POS] in the Treatment of Asymptomatic Chro

242 e at a dose of 400 mg twice daily (high-dose posaconazole), posaconazole at a dose of 100 mg twice da

243 gh-risk episodes, prospectively managed with posaconazole primary prophylaxis and a uniform diagnosti

244 it demonstrates in a real-life setting that posaconazole prophylaxis confers an advantage in terms o

245 in the IFD-associated mortality rate, while posaconazole prophylaxis had a significant impact on ove

246 During the last years, the use of posaconazole prophylaxis in high-risk patients has signi

247 isseminated fusariosis that occurred despite posaconazole prophylaxis.

248 (CSF), micafungin (MCF), fluconazole (FLC), posaconazole (PSC), and voriconazole (VRC) for six rarer

249 itraconazole (ITRA), voriconazole (VRC), and posaconazole (PSZ) in 24 isolates of Candida glabrata wi

250 The investigational triazoles posaconazole, ravuconazole, and voriconazole had excelle

251 The investigational triazoles posaconazole, ravuconazole, and voriconazole were all hi

252 27-A2 document) MICs of three new triazoles (posaconazole, ravuconazole, and voriconazole) and the ec

253 ) and exhibited variable cross-resistance to posaconazole, ravuconazole, and voriconazole.

254 n B, flucytosine, fluconazole, itraconazole, posaconazole, ravuconazole, and voriconazole.

255 ility in three laboratories of itraconazole, posaconazole, ravuconazole, voriconazole, and amphoteric

256 to amphotericin B, flucytosine, fluconazole, posaconazole, ravuconazole, voriconazole, and caspofungi

257 the Etest method to detect voriconazole and posaconazole resistance among Aspergillus spp.

258 2.3, 79% for voriconazole and 6, 12 mg/mL of posaconazole, respectively.

259 The performance of the Etest for posaconazole (SCH 56592) susceptibility testing of 314 i

260 Posaconazole showed antitrypanosomal activity in patient

261 . except C. glabrata (10.5% non-WT), whereas posaconazole showed decreased activity against C. albica

262 h a combination of intranasal PC945 and oral posaconazole survived until day 7, while little protecti

263 ppears to be a useful method for determining posaconazole susceptibilities of Candida species.

264 ple and reliable methods for determining the posaconazole susceptibilities of filamentous fungi.

265 ds a viable alternative to microdilution for posaconazole susceptibility testing.

266 ents may be useful as a surrogate marker for posaconazole susceptibility.

267 applied the voriconazole MIC breakpoints to posaconazole (susceptible, < or =1 microg/ml; susceptibl

268 The exceptions were the results for posaconazole tablets (R, 0.686; disk, 0.757; 84% categor

269 microg caspofungin and 1-microg voriconazole posaconazole tablets against all mold isolates, 8-microg

270 Posaconazole tablets are well tolerated and efficacious

271 Combination posaconazole-tacrolimus therapy displays synergism in vi

272 ox, fluconazole, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole.

273 ox, fluconazole, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole.

274 The antifungal drug posaconazole that blocks sterol biosynthesis in the para

275 For posaconazole, the agreement was higher with M3 media (91

276 For posaconazole, the correlation was acceptable for Mucorom

277 ombination lipid polyene plus deferasirox or posaconazole therapy.

278 ent occurred within 6 weeks of initiation of posaconazole therapy; after 6 months, infection had reso

279 e absence of clinical breakpoints (CBPs) for posaconazole, these WT distributions and ECVs will be us

280 Agreement ranged from 92.3% with posaconazole to 98.0% with fluconazole.

281 tored in patients treated concomitantly with posaconazole to avoid toxicity from drug interaction.

282 but the infection continued to progress, so posaconazole treatment was begun and eventually led to t

283 n, 5-flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, and amphotericin B by CLSI m

284 of isavuconazole, itraconazole, fluconazole, posaconazole, voriconazole, and the three echinocandins

285 gs tested were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin,

286 amined the in vitro activity of caspofungin, posaconazole, voriconazole, ravuconazole, itraconazole,

287 Posaconazole was conjugated with the fluorophore boron-d

288 Posaconazole was found to inhibit amoeba growth within t

289 Among the triazoles, posaconazole was most active, inhibiting 95% of isolates

290 Cross-resistance between itraconazole and posaconazole was seen for 53.5% of the isolates, whereas

291 Posaconazole was the most frequently prescribed drug (26

292 Posaconazole was well tolerated and effective against IF

293 Treatment with posaconazole was well tolerated and induced a complete c

294 fluconazole, itraconazole, voriconazole, and posaconazole were compared to reference 48-h microdiluti

295 Sixty-nine patients receiving posaconazole were included, of whom 16 (23.2%) met the d

296 The MICs of amphotericin B and posaconazole were the lowest, and the MICs of triazoles

297 hese results suggest that the combination of posaconazole with the HIV protease inhibitors warrants f

298 f 2 antifungals, amphotericin B products and posaconazole, with activity against Mucorales.

299 Benznidazole monotherapy is superior to posaconazole, with high RT-PCR conversion rates sustaine

300 eukemia, which was treated successfully with posaconazole without recurrence after a hematopoietic st